PRAS40 is a functionally critical target for EWS repression in Ewing sarcoma

Cancer Research

Volumn 72, Issue 5, 2012, Pages 1260-1269

  Huang, Lin ^a   Nakai, Yuji ^c   Kuwahara, Iku ^a   Matsumoto, Ken ^a,b  

^a RIKEN   (Japan)

^b JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; ONCOPROTEIN; PROTEIN PRAS40; RNA BINDING PROTEIN EWS; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ARTICLE; BINDING AFFINITY; CARCINOGENESIS; CELL PROLIFERATION; CONTROLLED STUDY; EWING SARCOMA; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; MITOSIS INHIBITION; ONCOGENE; PRAS40 GENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; ONCOGENE PROTEINS, FUSION; PROTO-ONCOGENE PROTEIN C-FLI-1; RNA-BINDING PROTEIN EWS; SARCOMA, EWING;

EID: 84857710881     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-11-2254     Document Type: Article

References (45)

1. Deneen B, Denny CT. Loss of p16 pathways stabilizes EWS/FLI1 expression and complements EWS/FLI1 mediated transformation. Oncogene 2001;20:6731-41. (Pubitemid 33020602)
2. Sohn EJ, Li H, Reidy K, Beers LF, Christensen BL, Lee SB. EWS/FLI1 oncogene activates caspase 3 transcription and triggers apoptosis in vivo. Cancer Res 2010;70:1154-63.
3. Lin PP, Pandey MK, Jin F, Xiong S, Deavers M, Parant JM, et al. EWSFLI1 induces developmental abnormalities and accelerates sarcoma formation in a transgenic mouse model. Cancer Res 2008;68:8968-75.
4. Neilsen PM, Pishas KI, Callen DF, Thomas DM. Targeting the p53 pathway in Ewing Sarcoma. Sarcoma 2011;2011:746939.
5. Kovar H, Jug G, Hattinger C, Spahn L, Aryee DN, Ambros PF, et al. The EWS protein is dispensable for Ewing tumor growth. Cancer Res 2001;61:5992-7. (Pubitemid 32762526)
6. Bertolotti A, Melot T, Acker J, Vigneron M, Delattre O, Tora L. EWS, but not EWS-FLI-1, is associated with both TFIID and RNA polymerase II: interactions between two members of the TET family, EWS and hTAFII68, and subunits of TFIID and RNA polymerase II complexes. Mol Cell Biol 1998;18:1489-97. (Pubitemid 28100914)
7. Petermann R, Mossier BM, Aryee DN, Khazak V, Golemis EA, Kovar H. Oncogenic EWS-Fli1 interacts with hsRPB7, a subunit of human RNA polymerase II. Oncogene 1998;17:603-10. (Pubitemid 28401029)
8. Rossow KL, Janknecht R. The Ewing's sarcoma gene product functions as a transcriptional activator. Cancer Res 2001;61:2690-5. (Pubitemid 32685856)
9. Araya N, Hirota K, Shimamoto Y, Miyagishi M, Yoshida E, Ishida J, et al. Cooperative interaction of EWS with CREB-binding protein selectively activates hepatocyte nuclear factor 4-mediated transcription. J Biol Chem 2003;278:5427-32. (Pubitemid 36801059)
10. Knoop LL, Baker SJ. The splicing factor U1C represses EWS/FLI-mediated transactivation. J Biol Chem 2000;275:24865-71. (Pubitemid 30626591)
11. Yang L, Chansky HA, Hickstein DD. EWS.Fli-1 fusion protein interacts with hyperphosphorylated RNA polymerase II and interferes with serine-arginine protein-mediated RNA splicing. J Biol Chem 2000;275: 37612-8. (Pubitemid 32004872)
12. Chansky HA, Hu M, Hickstein DD, Yang L. Oncogenic TLS/ERG and EWS/Fli-1 fusion proteins inhibit RNA splicing mediated by YB-1 protein. Cancer Res 2001;61:3586-90. (Pubitemid 32694966)
13. Paronetto MP, Minana B, Valcarcel J. The Ewing sarcoma protein regulates DNA damage-induced alternative splicing. Mol Cell 2011;43:353-68.
14. Dutertre M, Sanchez G, De Cian MC, Barbier J, Dardenne E, Gratadou L, et al. Cotranscriptional exon skipping in the genotoxic stress response. Nat Struct Mol Biol 2010;17:1358-66.
15. Zakaryan RP, Gehring H. Identification and characterization of the nuclear localization/retention signal in the EWS proto-oncoprotein. J Mol Biol 2006;363:27-38. (Pubitemid 44414847)
16. Andersson MK, Stahlberg A, Arvidsson Y, Olofsson A, Semb H, Stenman G, et al. The multifunctional FUS, EWS and TAF15 proto-oncoproteins show cell type-specific expression patterns and involvement in cell spreading and stress response. BMC Cell Biol 2008;9:37.
17. Aoki K, Matsumoto K, Tsujimoto M. Xenopus cold-inducible RNA-binding protein 2 interacts with ElrA, the Xenopus homolog of HuR, and inhibits deadenylation of specific mRNAs. J Biol Chem 2003;278: 48491-7. (Pubitemid 37523305)
18. Kovacina KS, Park GY, Bae SS, Guzzetta AW, Schaefer E, Birnbaum MJ, et al. Identification of a proline-rich Akt substrate as a 14-3-3 binding partner. J Biol Chem 2003;278:10189-94. (Pubitemid 36800278)
19. Fonseca BD, Smith EM, Lee VH, MacKintosh C, Proud CG. PRAS40 is a target for mammalian target of rapamycin complex 1 and is required for signaling downstream of this complex. J Biol Chem 2007;282: 24514-24. (Pubitemid 47347551)
20. Oshiro N, Takahashi R, Yoshino K, Tanimura K, Nakashima A, Eguchi S, et al. The proline-rich Akt substrate of 40 kDa (PRAS40) is a physiological substrate of mammalian target of rapamycin complex 1. J Biol Chem 2007;282:20329-39. (Pubitemid 47100038)
21. Sancak Y, Thoreen CC, Peterson TR, Lindquist RA, Kang SA, Spooner E, et al. PRAS40 is an insulin-regulated inhibitor of themTORC1protein kinase. Mol Cell 2007;25:903-15. (Pubitemid 46436534)
22. Vander Haar E, Lee SI, Bandhakavi S, Griffin TJ, Kim DH. Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40. Nat Cell Biol 2007;9:316-23. (Pubitemid 46344611)
23. Wang L, Harris TE, Roth RA, Lawrence JC Jr. PRAS40 regulates mTORC1 kinase activity by functioning as a direct inhibitor of substrate binding. J Biol Chem 2007;282:20036-44. (Pubitemid 47100127)
24. Nascimento EB, Ouwens DM. PRAS40: target or modulator of mTORC1 signalling and insulin action? Arch Physiol Biochem 2009; 115:163-75.
25. Ohno T, Ouchida M, Lee L, Gatalica Z, Rao VN, Reddy ES. The EWS gene, involved in Ewing family of tumors, malignant melanoma of soft parts and desmoplastic small round cell tumors, codes for an RNA binding protein with novel regulatory domains. Oncogene 1994;9: 3087-97. (Pubitemid 24296791)
26. Takahama K, Kino K, Arai S, Kurokawa R, Oyoshi T. Identification of Ewing's sarcoma protein as a G-quadruplex DNA- and RNA-binding protein. Febs J 2011;278:988-98.
27. Ordonez JL, Osuna D, Herrero D, de Alava E, Madoz-Gurpide J. Advances in Ewing's sarcoma research: where are we now and what lies ahead? Cancer Res 2009;69:7140-50.
28. Benini S, Manara MC, Cerisano V, Perdichizzi S, Strammiello R, Serra M, et al. Contribution of MEK/MAPK and PI3-K signaling pathway to the malignant behavior of Ewing's sarcoma cells: therapeutic prospects. Int J Cancer 2004;108:358-66. (Pubitemid 37549600)
29. Lawlor ER, Scheel C, Irving J, Sorensen PH. Anchorage-independent multi-cellular spheroids as an in vitro model of growth signaling in Ewing tumors. Oncogene 2002;21:307-18. (Pubitemid 34102139)
30. Yamamoto T, Ohno T,Wakahara K, Nagano A, Kawai G, Saitou M, et al. Simultaneous inhibition of mitogen-activated protein kinase and phosphatidylinositol 3-kinase pathways augment the sensitivity to actinomycin D in Ewing sarcoma. J Cancer Res Clin Oncol 2009;135: 1125-36.
31. Toretsky JA, Thakar M, Eskenazi AE, Frantz CN. Phosphoinositide 3- hydroxide kinase blockade enhances apoptosis in the Ewing's sarcoma family of tumors. Cancer Res 1999;59:5745-50.
32. Madhunapantula SV, Sharma A, Robertson GP. PRAS40 deregulates apoptosis in malignant melanoma. Cancer Res 2007;67:3626-36. (Pubitemid 46762147)
33. Staege MS, Hutter C, Neumann I, Foja S, Hattenhorst UE, Hansen G, et al. DNA microarrays reveal relationship of Ewing family tumors to both endothelial and fetal neural crest-derived cells and define novel targets. Cancer Res 2004;64:8213-21. (Pubitemid 39491758)
34. Terrier P, Llombart-Bosch A, Contesso G. Small round blue cell tumors in bone: prognostic factors correlated to Ewing's sarcoma and neuroectodermal tumors. Semin Diagn Pathol 1996;13: 250-7. (Pubitemid 26282691)
35. Subbiah V, Anderson P. Targeted Therapy of Ewing's Sarcoma. Sarcoma 2011;2011:686985.
36. Olmos D, Postel-Vinay S, Molife LR, Okuno SH, Schuetze SM, Paccagnella ML, et al. Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study. Lancet Oncol 2010;11:129-35.
37. Kurzrock R, Patnaik A, Aisner J, Warren T, Leong S, Benjamin R, et al. A phase I study of weekly R1507, a human monoclonal antibody insulinlike growth factor-I receptor antagonist, in patients with advanced solid tumors. Clin Cancer Res 2010;16:2458-65.
38. Toretsky JA, Gorlick R. IGF-1R targeted treatment of sarcoma. Lancet Oncol 2010;11:105-6.
39. Erkizan HV, Kong Y, Merchant M, Schlottmann S, Barber-Rotenberg JS, Yuan L, et al. A small molecule blocking oncogenic protein EWSFLI1 interaction with RNA helicase A inhibits growth of Ewing's sarcoma. Nat Med 2009;15:750-6.
40. Chansky HA, Barahmand-Pour F, Mei Q, Kahn-Farooqi W, Zielinska- Kwiatkowska A, Blackburn M, et al. Targeting of EWS/FLI-1 by RNA interference attenuates the tumor phenotype of Ewing's sarcoma cells in vitro. J Orthop Res 2004;22:910-7. (Pubitemid 38756277)
41. Takigami I, Ohno T, Kitade Y, Hara A, Nagano A, Kawai G, et al. Synthetic siRNA targeting the breakpoint of EWS/Fli-1 inhibits growth of Ewing sarcoma xenografts in a mouse model. Int J Cancer 2011; 128:216-26.
42. Li H, Watford W, Li C, Parmelee A, Bryant MA, Deng C, et al. Ewing sarcoma gene EWS is essential for meiosis and B lymphocyte development. J Clin Invest 2007;117:1314-23. (Pubitemid 46718419)
43. Feun LG, Blessing JA, Barrett RJ, Hanjani P. A phase II trial of tricyclic nucleoside phosphate in patients with advanced squamous cell carcinoma of the cervix. A Gynecologic Oncology Group Study. Am J Clin Oncol 1993;16:506-8.
44. Schilcher RB, Haas CD, Samson MK, Young JD, Baker LH. Phase I evaluation and clinical pharmacology of tricyclic nucleoside 5′-phosphate using a weekly intravenous regimen. Cancer Res 1986;46: 3147-51. (Pubitemid 16074342)
45. Wang YH, Huang ML. Reduction of Lobe leads to TORC1 hypoactivation that induces ectopic Jak/STAT signaling to impair Drosophila eye development. Mech Dev 2009;126:781-90.